I'm Dr.. Pretty Bazra and I am a failure. And I say that not as a confession. I say it as a celebration. Over the all the times that I've failed, I started to notice a pattern almost like a system. And it took me a little while to name that system. I now call it fail mental fitness framework. So I'll talk to you about that a little bit later on. But before that, I'd like to take you back to the classroom. So, I'm an optometrist. I deal with numbers every single day. I own three businesses which again lot of ...

Core Concept - The brain is likened to a computer with components such as the prefrontal cortex (operating system), limbic system (emotional headquarters), amygdala (alarm/firewall), and neuroplasticity (software update) [2][3][4] - A mental breakdown is not a sign of weakness but a reset mechanism indicating the brain's current wiring is insufficient [16] - Healing from a breakdown involves a process that may initially worsen symptoms before improvement [10][11] Brain Function During Stress - Constant stress triggers the amygdala, acting as a smoke detector, to sound an alarm [5][6] - During a breakdown, the prefrontal cortex, responsible for logic, memory, and problem-solving, becomes overwhelmed, leading to a shutdown of these functions [7][8] - Raw emotions from the amygdala, such as anger, aggression, and sadness, surge during a breakdown, causing a feeling of loss of control [8] Neuroplasticity and Recovery - Neuroplasticity is the brain's ability to rewire itself, enabling recovery and growth after a breakdown [4][14] - New choices, prayers, and exercises can create new neural pathways, calming the amygdala, strengthening the prefrontal cortex, and restoring balance [15] - The brain that experiences a breakdown is the same brain capable of rebuilding and functioning effectively [14][15]

Summary of NRx Pharmaceuticals Conference Call (October 08, 2025) Company Overview - NRx Pharmaceuticals is a micro-cap biotechnology company focused on developing treatments for mental health conditions, particularly suicidal ideation and depression [3][4] Key Programs and Developments - **NRX-100**: An intravenous ketamine formulation aimed at treating suicidal ideation and depression, with a fast-track indication granted by the FDA. The company is engaging with the FDA for a new drug application (NDA) [4][3] - **Market Potential**: The addressable market for NRX-100 is estimated to exceed $2 billion, based on the efficacy data from clinical trials and real-world data from over 180,000 patients treated with ketamine [4] - **NRX-101**: A fixed-dose combination of D-cycloserine and lurasidone, which has received breakthrough therapy designation. It aims to reduce suicidality in patients with akathisia [5][6] - **Hope Therapeutics Clinics**: The company is establishing a network of clinics to integrate medications with neuroplastic therapies like transcranial magnetic stimulation (TMS) and hyperbaric oxygen therapy [6][8] Competitive Landscape - **Johnson & Johnson's S-ketamine**: The only approved nasal spray for depression, which does not lower suicidality. It generated $1.3 billion in sales last year [5] - **Market Dynamics**: There is a current market of $750 million for ketamine, which is often in chronic shortage, leading providers to compounding pharmacies [8] Clinical Insights and Data - **PTSD Treatment**: Recent studies indicate that intravenous ketamine significantly reduces PTSD symptoms, with 12 million Americans affected by PTSD and no approved drug available [8][9] - **Suicidality Statistics**: Over 50,000 Americans die by suicide annually, with significant numbers of individuals contemplating or attempting suicide [10] - **Neuroplasticity**: The company emphasizes the neurobiological understanding of suicidality, focusing on NMDA receptor antagonists to promote neuroplasticity and improve treatment outcomes [11][13] Regulatory and Strategic Initiatives - **FDA Engagement**: The company is pursuing a Commissioner's National Priority Voucher (CNPV) to expedite the NDA process for NRX-100, which could significantly shorten the timeline for approval [4][27] - **Citizen's Petition**: NRx Pharmaceuticals has filed a petition with the FDA to remove toxic preservatives from ketamine formulations [7] Future Directions - **Combination Therapies**: The company plans to integrate various treatment modalities, including neuroplastic drugs, TMS, hyperbaric oxygen therapy, and digital therapeutics, to create a comprehensive treatment approach for suicidal depression and PTSD [22][24] - **Cost-Effectiveness**: The treatment courses proposed by NRx Pharmaceuticals are expected to be significantly less expensive than traditional interventions for other serious health conditions, costing less than $10,000 [23] Government and Regulatory Support - **Administration Focus**: The current administration has prioritized mental health, particularly veteran suicide prevention, indicating a supportive environment for innovative treatments like those being developed by NRx Pharmaceuticals [24][25] Conclusion - NRx Pharmaceuticals is positioned to address critical gaps in the treatment of suicidal ideation and depression through innovative drug development and integrated therapeutic approaches, with significant market potential and supportive regulatory pathways ahead [3][4][22]

Neuroscience of Adolescence - Adolescence is a unique window of opportunity due to increased neuroplasticity, the brain's ability to reorganize itself and form new neural connections [2][5] - During teenage years, brains are most adaptable, primed for learning and growth, but also highly susceptible to negative influences [5] - Environments directly impact brain growth, highlighting the importance of harnessing neuroplasticity to focus, adapt, and thrive [6] - Neuroscience reveals adolescence is about brains actively shaping who individuals become, with neuroplasticity at its peak [7] Enhancing Focus and Habits - Exercise and mindfulness produce brain-derived neurotrophic factor (BDNF), a protein that supports neurogenesis, the production of new neurons [8] - Neuroplasticity thrives on challenge, novelty, and even failure, as brains form new connections in uncomfortable situations [8][9] - Focus is about saying yes to the right things, activating the prefrontal cortex, the brain's CEO responsible for decision making and planning [10][11] - Small achievements release dopamine, the brain's feel-good neurotransmitter, suggesting breaking down goals into smaller, manageable tasks [12][13] - Multitasking is ineffective; the brain prefers doing one thing well, and switching between tasks leads to lost time and productivity [13][14] - Habit stacking involves pairing a new habit with an existing one to prime the brain for focus and growth [15] Influence of Environment and Social Connections - Individuals mirror the behaviors of those around them due to mirror neurons, emphasizing the importance of surrounding oneself with optimistic and supportive people [17][18] - Being intentional with what one consumes and being an inspiration for others can create a ripple effect of positive influence [19][20]

Albert Einstein once said, "Reality is merely an illusion, albeit a very persistent one. " But what if I told you that your brain is shaping that illusion every second? Imagine a scenario where two different people are stuck in traffic. One is frustrated, holding on to the wheel, thinking, "Why does this always happen to me. Now, at the same time, the other person looks at the delay in a unique way.A chance to enjoy their favorite podcast. Same situation, completely different experiences. Why.There is just ...

Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device DesignationNEWTOWN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), today announced the filing of its U.S. Food and Drug Administration (FDA) 510(k) submission for the PoNS (Portable Neuromodulation Stimulator) device label expansion seeking an indication for gait and balance deficit in patients with chronic stroke symptoms. The submission was ...

Almost exactly three years ago today, I made my history making professional boxing debut. I was about to become Saudi Arabia's first ever professional boxer in history. Amazing, right? Great. But there was one problem. I've never done it before. No one's ever done it before. But what if there was a way? What if there was a way for me to do it before I actually do it? What if there was a way for us to do something before we actually do it? The truth is, I've already fought this fight a 100 times in my head. ...

I want to begin with a phrase that I wish someone had said to me years ago. A phrase that I hope each of you will remember. You are not broken.Maybe you just like cringed a little when I said that, right. Maybe you don't believe me or believe it. Maybe, like me, you've spent years convinced that something within you is fundamentally flawed.that you're a little too anxious, a little too sensitive, maybe somehow just too much. For so long, I lived with this haunting question of what's wrong with me. And it co ...

emerged from a point of infinite density and zero volume. A singularity nothingness. Isn't that crazy.And somehow here we are panicking about college applications, exam scores, and how we what we're going to do with our lives. We live in a world obsessed with proof. proof of our potential, proof of our worth, proof that you're going somewhere successful.And if you don't have these things yet, if you're still figuring it out, it's easy to feel like you're already behind. But here's the perspective I wish to ...

Core Insights - NRx Pharmaceuticals is set to launch HOPE Therapeutics clinics in Fall 2025, focusing on treating suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction through a unique one-week residential program that combines various therapies [1][5] - The program will be the first of its kind in the nation, integrating neuroplastic drugs like ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy, along with nutritional therapy and supportive therapy [1][6] - The company recently raised over $8.8 million from biotechnology investors to support its initiatives, with no warrants or variable rate features involved [3][5] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD [4] - The company is advancing neuroplastic drug development, particularly NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression [4] - HOPE Therapeutics, a subsidiary of NRx, aims to create a network of interventional psychiatry clinics offering innovative therapies for patients with suicidal depression and related disorders [6] Key Partnerships and Initiatives - Matthew Rockefeller has joined the advisory board of HOPE Therapeutics, enhancing the company's strategic direction [1][3] - The Global Passion Project, founded by Andrea Cartier Bartzen, emphasizes collaboration and innovation to address global challenges like suicidal depression and PTSD [2]